KALARIS THERAPEUTICS INC (KLRS)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$2.36+16.83%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · KLRS
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -71.6% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-11-05 · Compared with 117 industry peers
KLRS — litigation filed
Dated 2026-07-17
Other Events. On July 17, 2026, the Company issued a press release announcing positive additional data from its Phase 1a SAD clinical trial of TH103 in treatment-naïve patients with nAMD. Data from the expanded cohorts build on previously reported positive findings from the trial, with additional patients showing improvements in vision and retinal anatomy and further supporting the potential for extended treatment durability after a standard four-dose loading regimen. The expanded Phase 1a SA…
Why it matters: The study will test repeated doses and help pick a dose for later trials. Clear safety and vision gains would support moving TH103 forward.
Supportive ifIn the first half of 2027, Kalaris reports Phase 1b/2 data. The data show good safety and better vision or eye scans after repeat doses.
Worry ifKalaris reports serious safety issues or no gains in vision or eye scans. Or, it delays the data past the first half of 2027.
Why it matters: Early data showed some patients waited months before another treatment. Repeat-dose results can show if that finding lasts with more patients.
Supportive ifPhase 1b/2 data show many patients go at least four months after loading doses before another treatment. Results are reported by patient count.
Worry ifMost Phase 1b/2 patients need more treatment before four months. Or Kalaris says loading doses do not delay the next treatment.
Why it matters: Kalaris reports $93.5 million in cash and says it can fund work into Q4 2027. A shorter runway could put trial plans at risk.
Worry ifKalaris says its cash will last only until before Q4 2027, or reports less than $80 million in cash on November 11.
Less concerning ifKalaris keeps its stated runway into Q4 2027 or later and reports cash of at least $90 million.
Why it matters: Kalaris says Phase 3 trials remain on track to start by year-end 2027. A clear start plan would show progress toward its main clinical goal.
Supportive ifKalaris names Phase 3 trial sites, dose plans, or a start date, and begins a trial by December 31, 2027.
Worry ifKalaris delays the planned Phase 3 start past December 31, 2027, or says it will not move TH103 into Phase 3.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$290 on $10,000 · ±2.9% | How much price usually moves either way. |
| Bad day | $775 loss on $10,000 · 7.8% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $8,361 loss on $10,000 · 83.6% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.